Medically reviewed by Marla Anderson, MD Triple-negative breast cancer (TNBC) is difficult to treat due to its aggressive ...

The exact cause or causes of triple-negative breast cancer are unknown, but researchers have linked it to mutations in the BRCA1 and BRCA2 genes. They also have been able to identify certain risk ...

Triple-negative breast cancer (TNBC), a subgroup that lacks expression ... genes Breast cancers occurring in patients with germline BRCA1 mutations are often triple negative and basal like ...

Genetic testing may reveal mutations like BRCA1 or BRCA2 that influence both treatment decisions and recommendations for family members. Treating triple negative breast cancer presents unique ...

Research from Weill Cornell Medicine has identified a molecular pathway linking omega-6 linoleic acid—a common dietary fat in ...

Tumor-negative breast cancers misclassified as ... Adjuvant trastuzumab has significantly improved the prognosis of breast cancer patients both in terms of disease-free survival and overall ...

The most common reason cancer returns is due to microscopic cancer cells that survive the initial treatment. These cells can ...

Linoleic acid, an omega-6 fatty acid found in seed oils such as soybean and safflower oil, and animal products including pork and eggs, specifically enhances the growth of the hard-to-treat "triple ...

A groundbreaking research study led by Professor Solomon Rotimi of the Department of Biochemistry, Covenant University, has been published in the prestigious Technology in Cancer Research & Treatment ...

So according to NCCN, one should consider the addition of adjuvant olaparib for one year, for those with germline BRCA1/2 mutations, particularly for those who have triple-negative breast cancer ...

BRCA1 is a major breast cancer-causing ... Olopade acknowledged that researchers still don't know a lot about triple negative breast cancer and more study is needed. She encouraged all young ...

Triple-negative breast cancers are often characterized ... toxicity profile and objective responses in patients with BRCA1-associated cancer. As the authors highlight, genetically engineered ...